Chemclin Diagnostics Co., Ltd. (SHA:688468)

China flag China · Delayed Price · Currency is CNY
6.19
-0.12 (-1.90%)
Jun 4, 2026, 3:00 PM CST
Market Cap2.44B -14.1%
Revenue (ttm)324.73M -23.7%
Net Income38.33M -65.4%
EPS0.09 -65.6%
Shares Out 394.59M
PE Ratio67.88
Forward PEn/a
Dividend0.13 (1.85%)
Ex-Dividend DateJun 13, 2025
Volume3,225,976
Open6.30
Previous Close6.31
Day's Range6.13 - 6.35
52-Week Range6.15 - 9.12
Beta0.07
Analystsn/a
Price Targetn/a
Earnings DateAug 28, 2026

About Chemclin Diagnostics

Chemclin Diagnostics Co., Ltd. engages in the research and development, production, and sale of clinical immune chemiluminescence diagnostic reagents and instruments. Its products include LiCAA series of diagnostic reagents based on photo-induced chemiluminescence and CC series based on enzymatic chemiluminescence diagnostic reagents and instruments, primarily used for infectious diseases, such as hepatitis B, hepatitis C, AIDS, syphilis, hepatitis A, hepatitis E, etc.; and detection of tumor markers, thyroid hormones, reproductive endocrine ho... [Read more]

Sector Healthcare
Founded 2007
Employees 606
Stock Exchange Shanghai Stock Exchange
Ticker Symbol 688468
Full Company Profile

Financial Performance

In 2025, Chemclin Diagnostics's revenue was 332.68 million, a decrease of -23.75% compared to the previous year's 436.29 million. Earnings were 43.91 million, a decrease of -65.44%.

Financial Statements